Study finds Ebola vaccine working
Print Edition
AN experimental Ebola vaccine tested on thousands of people in Guinea seems to work and might help shut down the waning epidemic in West Africa, according to interim results from a study published yesterday.
There is currently no licensed treatment or vaccine for Ebola, which has so far killed more than 11,000 people in West Africa since the world’s biggest outbreak began in the forest region of Guinea last year.
Cases have dropped dramatically in recent months in the other two hard-hit countries, Sierra Leone and Liberia.
“If proven effective, this is going to be a game-changer,” said Dr Margaret Chan, director-general of the World Health Organization, which sponsored the study. “It will change the management of the current outbreak and future outbreaks.”
Scientists have struggled for years to develop Ebola treatments and vaccines but have faced numerous hurdles, including the sporadic nature of outbreaks and funding shortages. Many past attempts have failed, including a recently abandoned drug being tested in West Africa by Tekmira Pharmaceuticals.
For the study, researchers gave one dose of the new vaccine to more than 4,000 health care workers and other people within 10 days of their close contact with a sick Ebola patient. Another group of 3,500 people got the shot more than 10 days after their exposure to the infectious virus. In the group that received the vaccine immediately, there were no Ebola cases versus 16 cases in people who got delayed vaccination.
The vaccine, developed by the Canadian government, has since been licensed to Merck & Co but has not yet been approved by regulators. The study results were published online yesterday in the journal Lancet.
At the moment, officials think the vaccine would only be used once an outbreak starts, to protect those at high-risk; there are no plans to introduce mass vaccination campaigns like those for measles or polio or to create huge stockpiles of the shots.
Merck, based in Kenilworth, New Jersey, noted its vaccine is in what is normally the final round of human testing in Sierra Leone, and in mid-stage testing in Liberia.
Merck will manufacture the vaccine if it’s approved for use outside patient studies.
Last December, Gavi, the vaccine alliance, said it would spend up to US$300 million buying approved Ebola vaccines. The private-public partnership, which often buys immunizations for poor countries, said yesterday that it “stands ready to support the implementation of a WHO-recommended Ebola vaccine.”
An expert group monitoring the study’s data and safety recommended the trial be stopped on July 26 so that everyone exposed to Ebola in Guinea could be immunized. The vaccine uses an Ebola protein to prompt the body’s immune system to attack the virus.
“It looks to be about as safe as a flu vaccine,” said Ben Neuman, a virologist at the University of Reading. “This (vaccine) could be the key that we’ve been missing to end the outbreak,” Neuman said. “I don’t see any reason on humanitarian grounds why it should not be used immediately.”
WHO vaccines expert Marie-Paule Kieny said having an effective vaccine might avert future disasters but added it would still take months to get the shot approved by regulators.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
